STOCK TITAN
  1. Home
  2. News
  3. ADAP

Adaptimmune Therapeutics Plc - ADAP STOCK NEWS

Welcome to our dedicated page for Adaptimmune Therapeutics Plc news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics Plc stock.

About Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Plc (NASDAQ: ADAP) is a clinical-stage biopharmaceutical company revolutionizing cancer treatment through its pioneering work in engineered T-cell receptor (TCR) therapies. With headquarters in Philadelphia, Pennsylvania, and Oxford, United Kingdom, the company is focused on developing personalized immunotherapies to target and eradicate solid tumors, a historically challenging area in oncology.

Core Technology and Innovation

At the heart of Adaptimmune's innovation is its proprietary T-cell receptor platform, which enables the genetic engineering of T-cells to recognize and attack specific cancer antigens. This platform is designed to address a wide range of solid tumors, including sarcomas and other difficult-to-treat cancers. By leveraging advanced bioengineering techniques, Adaptimmune aims to transform the lives of patients with limited treatment options.

Key Therapeutic Programs

  • Afami-cel: The first engineered T-cell therapy for solid tumors, targeting MAGE-A4+ synovial sarcoma. Recently approved by the FDA, afami-cel represents a breakthrough in sarcoma treatment.
  • Lete-cel: A pipeline candidate targeting NY-ESO-1+ tumors, including synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Lete-cel has shown promising results in clinical trials and is expected to expand Adaptimmune's sarcoma franchise.
  • Uza-cel: A next-generation TCR T-cell therapy targeting MAGE-A4, developed in collaboration with Galapagos NV, with potential applications in head and neck cancers and other solid tumors.

Strategic Collaborations and Market Position

Adaptimmune has established strategic partnerships to enhance its research, development, and commercialization capabilities. Notable collaborations include agreements with Galapagos NV for decentralized manufacturing and previous partnerships with Genentech and GSK. These alliances underscore Adaptimmune's commitment to innovation and its ability to leverage external expertise to advance its mission.

Competitive Landscape

Operating in the highly competitive field of immuno-oncology, Adaptimmune differentiates itself through its focus on solid tumors and its robust pipeline of TCR therapies. Competitors in this space include Kite Pharma and Novartis, but Adaptimmune's proprietary technology and focus on addressing unmet medical needs provide a unique value proposition.

Future Outlook

With FDA approval for afami-cel and a strong pipeline of candidates like lete-cel, Adaptimmune is poised to redefine the treatment landscape for solid tumors. The company's focus on sarcoma and its innovative TCR platform position it as a leader in the cell therapy space, with significant potential for growth and impact in oncology.

News

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Rhea-AI Summary
Adaptimmune reappoints Cintia Piccina as Chief Commercial Officer to lead the launch of afami-cel for advanced synovial sarcoma treatment. The company aims to leverage her expertise in cell therapy and commercialization as they prepare for the product's market entry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
management earnings
-
News

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Rhea-AI Summary
Adaptimmune Therapeutics plc (ADAP) to report financial results and business updates for Q4 and full year 2023, with a live webcast scheduled on March 6, 2024. Investors can access the press release and webcast details on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
conferences
-
News

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Rhea-AI Summary
Adaptimmune Therapeutics plc announced that the U.S. FDA has accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. If approved, it will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in over a decade. The Prescription Drug User Fee Act (PDUFA) target action date is August 4, 2024. Clinical trials have shown an impressive response rate of ~39% among heavily pre-treated patients with advanced synovial sarcoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
clinical trial
News

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) announced plans for its emerging sarcoma franchise, projecting peak US sales of up to $400 million. The company aims to launch afami-cel in the US in 2024 and lete-cel in 2026. The pivotal trial for lete-cel met its primary endpoint for efficacy, and the company is funded into early 2026 with over $300 million, including existing balance sheet and projected payments from partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.33%
Tags
none
-
News

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) submits the first BLA for afami-cel, an engineered T-cell therapy for synovial sarcoma, to the FDA. Positive data from the pivotal trial SPEARHEAD-1 show better outcomes compared to historical control data. The submission is supported by the completion of the rolling BLA, making afami-cel eligible for Priority Review, potentially shortening the FDA's review timeline. The company is preparing for the commercial launch of afami-cel and the evolution of its sarcoma cell therapy franchise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
-
News

Adaptimmune Receives Transfer of IND for Lete-cel Program

Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) announces the transfer of the IND for letetresgene autoluecel (lete-cel) from GSK to Adaptimmune for the pivotal IGNYTE-ESO (NCT03967223) clinical trial. The interim analysis of the pivotal IGNYTE-ESO trial demonstrates a 40% response rate in people with synovial sarcoma or myxoid/round cell liposarcoma. The company plans to lay out its cell therapy sarcoma franchise, including afami-cel and lete-cel, in January 2024. Adaptimmune and GSK have agreed terms regarding the return of the NY-ESO program back to Adaptimmune, resulting in milestone-based payments totaling £30 million in relation to the transfer of the clinical trials for the NY-ESO targeted programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.66%
Tags
none
News

Adaptimmune Reports Third Quarter Financial Results and Business Update

Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP): Afami-cel's BLA submission on track for Q4 completion, showing superior survival rates for synovial sarcoma patients. SURPASS Phase 1 trial reports 75% response rate in ovarian, urothelial, and head & neck cancers. Pipeline update includes termination of Gavo-cel and TC-510 programs. Financially, the company's cash runway is confirmed into early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.54%
Tags
earnings
-
News

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) provides progress update on PRAME program (ADP-600), announcing 10x higher sensitivity to target peptide than competitors, entry into the clinic in 2024, and selection of next-gen approaches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.54%
Tags
none
-
News

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Rhea-AI Summary
Adaptimmune Therapeutics plc is set to present outcome data from Cohort 1 of its pivotal SPEARHEAD-1 trial at the Connective Tissue Oncology Society (CTOS) annual meeting. The data shows that approximately 39% of patients who received afami-cel had clinical responses, with a median duration of response of around 12 months. The median overall survival in the trial was approximately 17 months, compared to a historical median overall survival of less than 12 months for patients with synovial sarcoma who had received two or more prior lines of therapy. Additionally, 70% of patients who responded to afami-cel were alive two years post-treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none
News

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) reports positive interim analysis results from the IGNYTE-ESO trial with lete-cel for synovial sarcoma and MRCLS. 40% of patients had clinical responses, with a median duration of response of approximately 11 months. A small substudy showed an 80% response rate in treatment-naïve patients. Safety findings were consistent with previous data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none

FAQ

What is the current stock price of Adaptimmune Therapeutics Plc (ADAP)?

The current stock price of Adaptimmune Therapeutics Plc (ADAP) is $0.54 as of February 28, 2025.

What is the market cap of Adaptimmune Therapeutics Plc (ADAP)?

The market cap of Adaptimmune Therapeutics Plc (ADAP) is approximately 141.0M.

What does Adaptimmune Therapeutics Plc specialize in?

Adaptimmune specializes in developing engineered T-cell receptor (TCR) therapies to treat solid tumors, including sarcomas and other difficult-to-treat cancers.

What is Adaptimmune's proprietary technology?

Adaptimmune's proprietary T-cell receptor (TCR) platform enables the genetic engineering of T-cells to target specific cancer antigens, providing a novel approach to treating solid tumors.

What are Adaptimmune's key therapeutic programs?

The company's key programs include afami-cel, the first FDA-approved T-cell therapy for solid tumors, and lete-cel, targeting NY-ESO-1+ tumors like synovial sarcoma and MRCLS.

How does Adaptimmune generate revenue?

Adaptimmune generates revenue through strategic collaborations, licensing agreements, and the anticipated commercialization of its pipeline products.

What makes Adaptimmune unique in the immuno-oncology space?

Adaptimmune's focus on solid tumors, robust pipeline, and proprietary TCR platform differentiate it from competitors in the immuno-oncology field.

Who are Adaptimmune's competitors?

Competitors include Kite Pharma and Novartis, which also focus on engineered cell therapies, though Adaptimmune's emphasis on sarcoma provides a unique edge.

What is afami-cel?

Afami-cel is Adaptimmune's FDA-approved T-cell therapy targeting MAGE-A4+ synovial sarcoma, representing a breakthrough in solid tumor treatment.

What is lete-cel?

Lete-cel is an investigational TCR therapy targeting NY-ESO-1+ tumors, with potential applications in synovial sarcoma and MRCLS.

What challenges does Adaptimmune face?

Challenges include high R&D costs, regulatory hurdles, and competition from other cell therapy companies in the immuno-oncology space.

What is the future outlook for Adaptimmune?

With FDA approval for afami-cel and a strong pipeline, Adaptimmune is well-positioned to lead in the treatment of solid tumors and expand its commercial footprint.
Stock ADAP logo
Adaptimmune Therapeutics Plc

Nasdaq:ADAP

ADAP Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ADAP Stock Data

141.02M
255.07M
0.38%
60.27%
2.09%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United Kingdom
ABINGDON, OXFORDSHIRE